BACKGROUND: New-onset diabetes after transplantation (NODAT) is a major posttransplant complication associated with lower allograft and recipient survival. Our objective was to determine whether metabolic syndrome pretransplant is independently associated with NODAT development. METHODS: We recruited 640 consecutive incident nondiabetic renal transplant recipients from three academic centers between 1999 and 2004. NODAT was defined as the use of hypoglycemic medication, a random plasma glucose level more than 200 mg/dL, or two fasting glucose levels more than or equal to 126 mg/dL beyond 30 days posttransplant. RESULTS: Metabolic syndrome was common pretransplant (57.2%). NODAT developed in 31.4% of recipients 1 year posttransplant. Participants with metabolic syndrome were more likely to develop NODAT compared with recipients without metabolic syndrome (34.4% vs. 27.4%, P=0.057). Recipients with increasing number of positive metabolic syndrome components were more likely to develop NODAT (metabolic syndrome score prevalence at 1 year: 0 components-0.0%, 1-24.2%, 2-29.3%, 3-31.0%, 4-34.8%, and 5-73.7%, P=0.001). After adjustment for demographics, age by decade (hazard ratio [HR] 1.34 [1.20-1.50], P<0.0001), African American race (HR 1.35 [1.01-1.82], P=0.043), cumulative prednisone dosage (HR 1.18 [1.07-1.30], P=0.001), and metabolic syndrome (HR 1.34 [1.00-1.79], P=0.047) were independent predictors of development of NODAT at 1 year posttransplant. In a multivariable analysis incorporating the individual metabolic syndrome components themselves as covariates, the only pretransplant metabolic syndrome component to remain an independent predictor of NODAT was low high-density lipoprotein (hazard ratio [HR] 1.37 [1.01-1.85], P=0.042). CONCLUSIONS: Metabolic syndrome is an independent predictor for NODAT and is a possible target for intervention to prevent NODAT. Future studies to evaluate whether modification of metabolic syndrome factors pretransplant reduces NODAT development are needed.
BACKGROUND: New-onset diabetes after transplantation (NODAT) is a major posttransplant complication associated with lower allograft and recipient survival. Our objective was to determine whether metabolic syndrome pretransplant is independently associated with NODAT development. METHODS: We recruited 640 consecutive incident nondiabetic renal transplant recipients from three academic centers between 1999 and 2004. NODAT was defined as the use of hypoglycemic medication, a random plasma glucose level more than 200 mg/dL, or two fasting glucose levels more than or equal to 126 mg/dL beyond 30 days posttransplant. RESULTS:Metabolic syndrome was common pretransplant (57.2%). NODAT developed in 31.4% of recipients 1 year posttransplant. Participants with metabolic syndrome were more likely to develop NODAT compared with recipients without metabolic syndrome (34.4% vs. 27.4%, P=0.057). Recipients with increasing number of positive metabolic syndrome components were more likely to develop NODAT (metabolic syndrome score prevalence at 1 year: 0 components-0.0%, 1-24.2%, 2-29.3%, 3-31.0%, 4-34.8%, and 5-73.7%, P=0.001). After adjustment for demographics, age by decade (hazard ratio [HR] 1.34 [1.20-1.50], P<0.0001), African American race (HR 1.35 [1.01-1.82], P=0.043), cumulative prednisone dosage (HR 1.18 [1.07-1.30], P=0.001), and metabolic syndrome (HR 1.34 [1.00-1.79], P=0.047) were independent predictors of development of NODAT at 1 year posttransplant. In a multivariable analysis incorporating the individual metabolic syndrome components themselves as covariates, the only pretransplant metabolic syndrome component to remain an independent predictor of NODAT was low high-density lipoprotein (hazard ratio [HR] 1.37 [1.01-1.85], P=0.042). CONCLUSIONS:Metabolic syndrome is an independent predictor for NODAT and is a possible target for intervention to prevent NODAT. Future studies to evaluate whether modification of metabolic syndrome factors pretransplant reduces NODAT development are needed.
Authors: Roy D Bloom; Vinaya Rao; Francis Weng; Robert A Grossman; Debbie Cohen; Kevin C Mange Journal: J Am Soc Nephrol Date: 2002-05 Impact factor: 10.121
Authors: Victor M Montori; Ananda Basu; Patricia J Erwin; Jorge A Velosa; Sherine E Gabriel; Yogish C Kudva Journal: Diabetes Care Date: 2002-03 Impact factor: 19.112
Authors: Fernando G Cosio; Todd E Pesavento; Sunny Kim; Kwame Osei; Mitchell Henry; Ronald M Ferguson Journal: Kidney Int Date: 2002-10 Impact factor: 10.612
Authors: Kevin C Abbott; Krista L Lentine; Jay R Bucci; Lawrence Y Agodoa; Jonathan M Koff; Kent C Holtzmuller; Mark A Schnitzler Journal: J Am Soc Nephrol Date: 2004-12 Impact factor: 10.121
Authors: Manfred Hecking; Johannes Werzowa; Michael Haidinger; Walter H Hörl; Julio Pascual; Klemens Budde; Fu L Luan; Akinlolu Ojo; Aiko P J de Vries; Esteban Porrini; Giovanni Pacini; Friedrich K Port; Adnan Sharif; Marcus D Säemann Journal: Nephrol Dial Transplant Date: 2013-01-17 Impact factor: 5.992
Authors: Rianne P Wauters; Fernando G Cosio; Maria L Suarez Fernandez; Yogish Kudva; Pankaj Shah; Vicente E Torres Journal: Transplantation Date: 2012-08-27 Impact factor: 4.939
Authors: Maria P Martinez Cantarin; Scott W Keith; Zhao Lin; Cataldo Doria; Adam M Frank; Warren R Maley; Carlo Ramirez; Costas D Lallas; Ashesh Shah; Scott A Waldman; Bonita Falkner Journal: Cardiorenal Med Date: 2016-05-18 Impact factor: 2.041
Authors: A Sharif; M Hecking; A P J de Vries; E Porrini; M Hornum; S Rasoul-Rockenschaub; G Berlakovich; M Krebs; A Kautzky-Willer; G Schernthaner; P Marchetti; G Pacini; A Ojo; S Takahara; J L Larsen; K Budde; K Eller; J Pascual; A Jardine; S J L Bakker; T G Valderhaug; T G Jenssen; S Cohney; M D Säemann Journal: Am J Transplant Date: 2014-08-06 Impact factor: 8.086
Authors: Phuong-Thu T Pham; Phuong-Mai T Pham; Son V Pham; Phuong-Anh T Pham; Phuong-Chi T Pham Journal: Diabetes Metab Syndr Obes Date: 2011-05-09 Impact factor: 3.168
Authors: Phuong-Thu T Pham; Kari L Edling; Harini A Chakkera; Phuong-Chi T Pham; Phuong-Mai T Pham Journal: Diabetes Metab Syndr Obes Date: 2012-10-26 Impact factor: 3.168
Authors: Harini A Chakkera; E Jennifer Weil; Phuong-Thu Pham; Jeremy Pomeroy; William C Knowler Journal: Diabetes Care Date: 2013-05 Impact factor: 19.112